Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
50.24M | 45.64M | 22.28M | 21.90M | 22.47M | Gross Profit |
11.48M | 12.03M | 10.12M | 7.73M | 8.85M | EBIT |
-20.09M | -4.59M | 417.00 | -1.43M | -1.85M | EBITDA |
-16.82M | 1.11M | 3.57M | 5.44M | 2.15M | Net Income Common Stockholders |
-17.96M | -3.14M | 468.00K | -246.21K | 1.26M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
14.93M | 26.76M | 26.05M | 25.91M | 25.95M | Total Assets |
58.87M | 62.22M | 40.27M | 33.77M | 39.41M | Total Debt |
14.52M | 10.08M | 4.45M | 1.87M | 5.50M | Net Debt |
4.08M | -10.12M | -10.93M | -14.39M | -13.10M | Total Liabilities |
26.09M | 24.73M | 15.68M | 9.75M | 13.92M | Stockholders Equity |
31.81M | 37.47M | 24.37M | 24.28M | 25.49M |
Cash Flow | Free Cash Flow | |||
0.00 | -3.15M | 3.06M | 2.73M | 7.25M | Operating Cash Flow |
0.00 | -1.91M | 4.24M | 3.34M | 7.38M | Investing Cash Flow |
0.00 | -6.51M | -1.15M | -2.64M | -6.04M | Financing Cash Flow |
0.00 | 13.62M | -3.72M | -4.81M | -4.15M |
Jinhai Medical Technology Limited announced its audited consolidated results for the year ended December 31, 2024. The company reported a revenue increase to S$50,241,000 from S$45,644,000 in 2023. However, the company faced a significant net loss of S$18,255,000, compared to a loss of S$4,112,000 in the previous year. The increase in administrative expenses and finance costs contributed to the widened loss. The announcement indicates challenges in managing costs, which may impact the company’s financial stability and investor confidence.
Jinhai Medical Technology Limited has issued a profit warning, indicating an expected loss of approximately S$18.1 million for the fiscal year 2024, compared to a loss of S$4.1 million in 2023. Despite a steady development in business operations with increased revenue, the rise in administrative expenses, particularly due to equity-settled share-based payments, has significantly impacted the financial results. Stakeholders are advised to exercise caution and await the audited annual results in March 2025.
Jinhai Medical Technology Limited has announced a board meeting scheduled for 28 March 2025 to discuss and approve the company’s annual results for the year ending 31 December 2024. The meeting will also consider the payment of a final dividend, which could have implications for shareholders and the company’s financial positioning.